Domestic studies have found that peripheral blood changes in sPD-L1 were associated with disease progression in patients with lung cancer before and after chemotherapy, but this study only included patients with lung squamous carcinoma and lung adenocarcinoma, and the changes in SCLC patients have not been fully studied [7]. This evidence concerns the gene SPDL1 and lung adenocarcinoma.